| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/20000 | Human,Mouse,Rat |
| Aliases | GDH2; GPDM; mGPDH |
| WB Predicted band size | 81 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human GPD2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于BRMS-1抗体的3篇参考文献及其简要摘要：
1. **文献名称**：*BRMS1 suppresses breast cancer metastasis by epigenetic regulation of the miR-29-HDAC4 axis*
**作者**：Liu Y. et al.
**摘要**：本研究利用BRMS-1抗体通过免疫沉淀和染色质免疫共沉淀(ChIP)技术，发现BRMS-1通过表观遗传调控miR-29/HDAC4信号通路抑制乳腺癌转移，揭示了其在调控组蛋白修饰中的分子机制。
2. **文献名称**：*BRMS1 as a prognostic biomarker in triple-negative breast cancer: A validation study*
**作者**：Smith J.R. et al.
**摘要**：该研究通过免疫组织化学(IHC)结合BRMS-1抗体，分析三阴性乳腺癌患者的组织样本，发现BRMS-1高表达与患者无转移生存期延长显著相关，提示其可作为预后标志物。
3. **文献名称**：*BRMS1 modulates AKT signaling and mitochondrial function in metastatic melanoma*
**作者**：Chen L. et al.
**摘要**：研究利用BRMS-1抗体进行Western blot和免疫荧光实验，证明BRMS-1通过抑制AKT通路并调节线粒体代谢功能，抑制黑色素瘤细胞的侵袭和转移能力。
注：以上文献信息为示例性内容，实际引用需以真实发表的论文为准。建议通过PubMed或Web of Science以“BRMS1 antibody”或“BRMS1 metastasis”为关键词检索最新文献。
BRMS1 (Breast Cancer Metastasis Suppressor 1) is a tumor metastasis suppressor gene initially identified for its role in inhibiting breast cancer metastasis without affecting primary tumor growth. The BRMS1 protein regulates multiple pathways involved in metastasis, including modulating gene expression through interactions with histone deacetylase (HDAC) complexes, suppressing NF-κB signaling, and restoring gap junctional communication. It also promotes apoptosis and inhibits angiogenesis, thereby limiting metastatic potential.
BRMS-1 antibodies are immunological tools developed to detect and quantify the BRMS1 protein in research settings. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study BRMS1 expression patterns in cancer tissues or cell lines. Reduced BRMS1 expression, often due to promoter hypermethylation or transcriptional repression, correlates with poor prognosis and increased metastatic risk in various cancers, including breast, ovarian, and melanoma.
Research utilizing BRMS-1 antibodies has contributed to understanding its role in metastasis regulation, epigenetic modifications, and potential therapeutic targeting. Such studies aim to uncover mechanisms underlying cancer progression and develop strategies to restore BRMS1 function as an anti-metastatic approach. Validating antibody specificity remains critical, as BRMS1 shares functional domains with other proteins, requiring careful experimental controls.
×
